Loncastuximab Tesirine and Epcoritamab

Phase 2

SOBI (SWTOY)

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Aggressive Diffuse Large B-cell Lymphoma

View Full Landscape

Drug Information

Target Indication

Aggressive Diffuse Large B-cell Lymphoma

Clinical Trial

NCT07197307

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA12/20/2022

Zynlonta

Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy.

Conditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SWTOY

SOBI

Healthcare•North America•NASDAQ

Related Pipeline

AvatrombopagPhase 3

Chemotherapy-induced Thrombocytopenia

Avatrombopag Oral TabletPhase 3

Immune Thrombocytopenia

EmapalumabPhase 2

Cytopenia

PacritinibPhase 2

Waldenström Macroglobulinemia

Fludarabine and DexamethasonePhase 2

Primary Immune Regulatory Disorder

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts